Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × venetoclax × Thoracic × Clear all

Phase

Status

Sponsor Class

INDUSTRY 4 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 271 Lymphoid 142 Myeloid 46 Plasma cell 10 Sarcoma 2 Other neoplasm 2 Genitourinary 2 Gastrointestinal 2 Breast 2 Tumor-Agnostic 1 Thoracic 1 Classical hematology 1

Conditions

Small Cell Lung Carcinoma 1

Interventions

Carboplatin 451 Cisplatin 364 Pemetrexed 361 Radiotherapy 253 Docetaxel 214 pembrolizumab 207 Paclitaxel 199 Erlotinib Hydrochloride 172 Bevacizumab 171 Gemcitabine 169 Drug Therapy 161 Radiosurgery 149 Nivolumab 147 durvalumab 141 Etoposide 135 osimertinib 109 atezolizumab 94 Magnetic Resonance Spectroscopy 85 Gefitinib 81 Vinorelbine 80 Surgical Procedures, Operative 75 Blood Specimen Collection 75 anlotinib 71 Ipilimumab 55 Specimen Handling 53 130-nm albumin-bound paclitaxel 53 Immunotherapy 52 Radiation 50 Irinotecan 50 Surveys and Questionnaires 49

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04543916 2021-03-03

Venetoclax and Irinotecan in Relapsed/Refractory SCLC

Virginia Commonwealth University

Phase 1/2 Withdrawn

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡